DK1887016T3 - Fragmenter af humant choriongonadotropin (HCG) som immunoregulator - Google Patents

Fragmenter af humant choriongonadotropin (HCG) som immunoregulator

Info

Publication number
DK1887016T3
DK1887016T3 DK07108784T DK07108784T DK1887016T3 DK 1887016 T3 DK1887016 T3 DK 1887016T3 DK 07108784 T DK07108784 T DK 07108784T DK 07108784 T DK07108784 T DK 07108784T DK 1887016 T3 DK1887016 T3 DK 1887016T3
Authority
DK
Denmark
Prior art keywords
immunoregulator
hcg
fragments
immune
chorionic gonadotropin
Prior art date
Application number
DK07108784T
Other languages
English (en)
Inventor
Nisar Ahmed Khan
Robbert Benner
Original Assignee
Biotempt Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotempt Bv filed Critical Biotempt Bv
Application granted granted Critical
Publication of DK1887016T3 publication Critical patent/DK1887016T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
DK07108784T 2000-03-29 2001-03-29 Fragmenter af humant choriongonadotropin (HCG) som immunoregulator DK1887016T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00201139A EP1138692A1 (en) 2000-03-29 2000-03-29 Fragments of human chorionic gonadotropin (hcg) as immunoregulator
PCT/NL2001/000259 WO2001072831A2 (en) 2000-03-29 2001-03-29 Immunoregulator

Publications (1)

Publication Number Publication Date
DK1887016T3 true DK1887016T3 (da) 2009-03-02

Family

ID=8171269

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01922133T DK1272515T3 (da) 2000-03-29 2001-03-29 Immunregulator
DK07108784T DK1887016T3 (da) 2000-03-29 2001-03-29 Fragmenter af humant choriongonadotropin (HCG) som immunoregulator

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK01922133T DK1272515T3 (da) 2000-03-29 2001-03-29 Immunregulator

Country Status (18)

Country Link
US (2) US7365155B2 (da)
EP (3) EP1138692A1 (da)
JP (1) JP5172064B2 (da)
KR (1) KR100800876B1 (da)
AT (2) ATE411340T1 (da)
AU (1) AU781632B2 (da)
CA (1) CA2407046C (da)
CY (2) CY1108706T1 (da)
DE (2) DE60136577D1 (da)
DK (2) DK1272515T3 (da)
ES (2) ES2315278T3 (da)
HK (1) HK1052360B (da)
IL (2) IL151945A0 (da)
NZ (1) NZ521703A (da)
PT (2) PT1272515E (da)
SG (1) SG127739A1 (da)
SI (2) SI1887016T1 (da)
WO (1) WO2001072831A2 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US7175679B2 (en) 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
EP1138692A1 (en) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US20040202645A1 (en) * 2003-04-08 2004-10-14 Khan Nisar Ahmed Administration of gene-regulatory peptides
US8680059B2 (en) 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US20050227925A1 (en) * 2004-04-08 2005-10-13 Robbert Benner Compositions capable of reducing elevated blood urea concentration
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
EP1300418A1 (en) 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
US20050037430A1 (en) * 2000-03-29 2005-02-17 Biotempt B.V. Methods and uses for protein breakdown products
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US7576174B2 (en) 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
US20030220259A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of neurological disorders
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US7501391B2 (en) 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US20030220260A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Peptide compositions
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US7560433B2 (en) * 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US20030224995A1 (en) * 2001-12-21 2003-12-04 Khan Nisar Ahmed Treatment of burns
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US20030220261A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
EP1466613A1 (en) * 2003-04-08 2004-10-13 Biotempt B.V. Compositions for mucosal and oral administration comprising hCG fragments
WO2004093897A1 (en) * 2003-04-08 2004-11-04 Biotempt, B.V. Compositions for mucosal and oral administration comprising hcg fragments
EP1466612A1 (en) * 2003-04-08 2004-10-13 Biotempt B.V. Treatment of inflammation and sepsis with hCG derived peptides
US7517529B2 (en) 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
EP1466611A1 (en) * 2003-04-08 2004-10-13 Biotempt B.V. Use of HCG derived peptides in the treatment of iatrogenic diseases
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
JP5252682B2 (ja) * 2005-02-25 2013-07-31 学校法人日本大学 哺乳動物ｔ細胞のサイトカインの分析方法と関連する一切の疾患の評価法と予防・治療の分析
WO2007004869A2 (en) * 2005-07-05 2007-01-11 Biotempt B.V. Treatment of tumors
DE102005054454A1 (de) * 2005-11-09 2007-06-28 Universität Duisburg-Essen Verwendung von Choriongonadotropin als Immunsuppressivum
EP1864692A1 (en) 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
DK2120991T3 (da) * 2007-02-12 2014-04-28 Biotempt Bv Behandling af traumatisk blødning med korte oligopeptider
US20080217002A1 (en) * 2007-03-07 2008-09-11 Floyd Randolph Simonds Sand control screen having a micro-perforated filtration layer
WO2009085180A1 (en) * 2007-12-20 2009-07-09 The Feinstein Institute For Medical Research Treatment of sepsis and inhibition of mif by d-t4
EP2109054A1 (en) 2008-04-09 2009-10-14 Biotempt B.V. Methods for identifying biologically active peptides and predicting their function
EP2490021A1 (en) 2011-02-18 2012-08-22 Biotempt B.V. Modulators of PRR and GPCR signalling
CN104415162B (zh) * 2013-08-21 2018-05-15 常州市肿瘤医院 治疗放化疗后白细胞减少症的中药组合物及其制备方法

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4571336A (en) 1983-08-25 1986-02-18 Endorphin, Inc. Immune stimulation
US4977244A (en) * 1985-06-27 1990-12-11 The United States Of America As Represented By The Department Of Health And Human Services Uromodulin and a process of purifying it
US4855285A (en) * 1985-12-04 1989-08-08 The Ohio State University Research Foundation Antigenic modification of polypeptides
NL8701113A (nl) 1986-05-12 1987-12-01 Wellcome Found Nieuwe farmaceutische toepassing.
US5055447A (en) 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
US5308834A (en) 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US6051596A (en) 1990-08-10 2000-04-18 Anormed, Inc. Immunosuppressive compositions
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
CA2102704A1 (en) 1991-05-17 1992-11-18 John Stephen Haskill Inhibitor of nf-kb transcriptional activator and uses thereof
DE4138621A1 (de) * 1991-11-25 1993-06-17 Boehringer Ingelheim Int Verfahren zum screenen von substanzen mit modulierender wirkung auf einen rezeptorabhaengigen zellulaeren signaluebertragungsweg
EP0633929B1 (en) * 1992-04-01 2004-03-03 The Rockefeller University METHOD FOR $i(IN VITRO) PROLIFERATION OF DENDRITIC CELL PRECURSORS AND THEIR USE TO PRODUCE IMMUNOGENS
ES2103854T3 (es) 1992-05-30 1997-10-01 Sikiric Predrag Peptidos con actividad organo protectiva, procedimiento para la preparacion de los mismos y su utilizacion en la terapia.
US5436270A (en) 1993-04-07 1995-07-25 National Science Council Method for protecting against endotoxin-induced shock
US5380668A (en) * 1993-07-06 1995-01-10 University Of Utah Research Foundation Compounds having the antigenicity of hCG
US5837478A (en) 1993-12-23 1998-11-17 Icos Corporation Method of identifying modulators of binding between and VCAM-1
US5677275A (en) 1994-08-05 1997-10-14 The United States Of America As Represented By The Department Of Health And Human Services Treatment of cancer with human chorionic gonadotropin
US5700781A (en) 1994-10-04 1997-12-23 Harris; Pamela Jo Method for treating Kaposi's sarcoma and HIV infections
US5851997A (en) * 1994-10-04 1998-12-22 Harris; Pamela Jo Use of human chorionic gonadotropin as an immune-potentiating antiviral agent
SE520730C2 (sv) 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
US5981486A (en) 1995-04-13 1999-11-09 Chugai Seiyaku Kabushiki Kaisha Peptide suppressing IκBα phosphorylation
WO1996033218A1 (en) 1995-04-21 1996-10-24 Allelix Biopharmaceuticals Inc. Anti-haemorrhagic peptides
US6361992B1 (en) * 1996-05-08 2002-03-26 The United States Of America As Represented By The Department Of Health And Human Services Thyroid stimulating hormone superagonists
US5997871A (en) * 1996-06-24 1999-12-07 University Of Maryland Biotechnology Insitute Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin
AU3587797A (en) * 1996-06-24 1998-01-14 University Of Maryland Biotechnology Institute Methods of treatment of wasting syndrome based on administration of derivatives of human chorionic gonadotropin
US5968513A (en) * 1996-06-24 1999-10-19 University Of Maryland Biotechnology Institute Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin
US6319504B1 (en) * 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US6150500A (en) 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
GB9617021D0 (en) 1996-08-13 1996-09-25 Salpep Biotechnology Inc Novel peptides for treatment of inflammation and shock
CA2279995A1 (en) 1997-02-07 1998-08-13 Thomas Jefferson University Peptide mimetics of the cytokine receptor gamma chain
ATE240113T1 (de) 1997-02-15 2003-05-15 Millennium Pharm Inc Behandlung von infarkten durch inhibierung von nf-kappab
US5801193A (en) 1997-04-15 1998-09-01 Immune Modulation, Inc. Compositions and methods for immunosuppressing
US6583109B1 (en) * 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
DE19735587B4 (de) 1997-08-16 2012-03-22 Eberhard-Karls-Universität Tübingen Universitätsklinikum Peptid mit radioprotektiver Wirkung, dieses enthaltende kosmetische oder pharmazeutische Zusammensetzung, für dieses kodierende Nukleinsäure, Herstellungsverfahren für dieses Peptid und die Verwendung als radioprotektives Agens
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
AU1552599A (en) 1997-12-12 1999-07-05 University Of Western Ontario, The Novel peptide, apoep1.b, compositions and uses thereof
US7175679B2 (en) * 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
WO1999059617A2 (en) * 1998-05-20 1999-11-25 Erasmus Universiteit Rotterdam Immunoregulator
US20030220258A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US6844315B2 (en) * 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
EP1138692A1 (en) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
RU2139085C1 (ru) 1998-06-23 1999-10-10 Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" Средство, стимулирующее репаративные процессы, и способ его применения
AU5722499A (en) 1998-09-17 2000-04-10 Hopital Sainte-Justine G protein-coupled receptor agonists or antagonists
JP2002531384A (ja) 1998-11-20 2002-09-24 マウント サイナイ ホスピタル ＢクラスｅｐｈｒｉｎとＰＤＺ領域との相互作用を変調するペプチド
US6507788B1 (en) 1999-02-25 2003-01-14 Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) Rational selection of putative peptides from identified nucleotide, or peptide sequences, of unknown function
AU3518700A (en) 1999-03-09 2000-09-28 James Edwin Blalock Synthetic complementary peptides and ophthalmologic uses thereof
US20030148955A1 (en) 1999-04-19 2003-08-07 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
RU2157233C1 (ru) * 1999-05-11 2000-10-10 Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" Тетрапептид, обладающий геропротекторной активностью, фармакологическое средство на его основе и способ его применения
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
CN1377276A (zh) 1999-08-09 2002-10-30 特里帕普股份公司 含有三肽的药用组合物
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
CA2387559A1 (en) 1999-10-15 2001-04-26 Histatek, Llc N-formyl peptide receptor complex with a g-protein kinase signal pathway modification agent
RU2155063C1 (ru) 1999-10-20 2000-08-27 Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" Тетрапептид, стимулирующий функциональную активность нейронов, фармакологическое средство на его основе и способ его применения
CA2389429C (en) 1999-11-18 2012-05-29 Victor E. Shashoua Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6630447B2 (en) 2000-01-14 2003-10-07 University Of New Mexico Peptide inhibitors of LFA-1/ICAM-1 interaction
CA2400187A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
AU2001245537A1 (en) 2000-03-10 2001-09-24 Monsanto Company Anti-hypertensive peptides
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
EP1300418A1 (en) 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
US7576174B2 (en) 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
US6783757B2 (en) * 2000-06-01 2004-08-31 Kirkman Group, Inc. Composition and method for increasing exorphin catabolism to treat autism
US6586403B1 (en) 2000-07-20 2003-07-01 Salpep Biotechnology, Inc. Treating allergic reactions and inflammatory responses with tri-and dipeptides
US20020155106A1 (en) 2000-12-01 2002-10-24 Hammond David J. Method of identifying a ligand for a target molecule
US20040198652A1 (en) 2001-04-24 2004-10-07 Carter J. Paul Methods and compositions for preventing and treating septic shock and endotoxemia
US20030220259A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of neurological disorders
US20030220261A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US7501391B2 (en) * 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US20030224995A1 (en) * 2001-12-21 2003-12-04 Khan Nisar Ahmed Treatment of burns
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US20030220260A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Peptide compositions
US20040013661A1 (en) * 2001-12-21 2004-01-22 Gert Wensvoort Stratification
US7560433B2 (en) * 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7135286B2 (en) * 2002-03-26 2006-11-14 Perlegen Sciences, Inc. Pharmaceutical and diagnostic business systems and methods
WO2003089922A1 (en) 2002-04-15 2003-10-30 American National Red Cross Method for detecting ligands and targets in a mixture
US7517529B2 (en) 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
WO2007004869A2 (en) 2005-07-05 2007-01-11 Biotempt B.V. Treatment of tumors
EP1864692A1 (en) 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury

Also Published As

Publication number Publication date
SI1272515T1 (sl) 2009-04-30
EP1887016B1 (en) 2008-11-12
US7365155B2 (en) 2008-04-29
CY1108706T1 (el) 2014-04-09
HK1052360A1 (en) 2003-09-11
NZ521703A (en) 2005-06-24
SG127739A1 (en) 2006-12-29
SI1887016T1 (sl) 2009-04-30
ES2315278T3 (es) 2009-04-01
PT1272515E (pt) 2009-01-23
EP1138692A1 (en) 2001-10-04
KR20030060768A (ko) 2003-07-16
PT1887016E (pt) 2009-02-20
CY1110259T1 (el) 2015-01-14
JP2004503468A (ja) 2004-02-05
EP1272515B1 (en) 2008-10-15
WO2001072831A2 (en) 2001-10-04
HK1052360B (zh) 2009-05-08
ATE411340T1 (de) 2008-10-15
AU781632B2 (en) 2005-06-02
DE60136169D1 (de) 2008-11-27
DE60136577D1 (de) 2008-12-24
USRE43140E1 (en) 2012-01-24
AU4891301A (en) 2001-10-08
EP1272515A2 (en) 2003-01-08
WO2001072831A3 (en) 2002-04-25
CA2407046C (en) 2011-02-15
DK1272515T3 (da) 2009-02-09
ES2317620T3 (es) 2009-04-16
US20030166556A1 (en) 2003-09-04
IL151945A (en) 2010-04-29
IL151945A0 (en) 2003-04-10
JP5172064B2 (ja) 2013-03-27
KR100800876B1 (ko) 2008-02-04
CA2407046A1 (en) 2001-10-04
ATE414104T1 (de) 2008-11-15
EP1887016A1 (en) 2008-02-13

Similar Documents

Publication Publication Date Title
DK1887016T3 (da) Fragmenter af humant choriongonadotropin (HCG) som immunoregulator
BR0317872A (pt) Medicamentos antiinflamatórios
ATE405647T1 (de) Rekombinantes gelatin in impstoffen
WO2003030934A3 (en) Cpg formulations and related methods
CY1114133T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ
DK1233784T3 (da) Præparater og fremgangsmåder til stabilisering af biologiske molekyler efter lyofilisering
BRPI0408247A (pt) usos de antagonistas e agonistas de il-23 e reagentes relacionados
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DK2287156T3 (da) 2,4-Di(phenylamino)-pyrimidiner egnede i behandling af neoplastiske sygdomme, inflammatoriske lidelser og lidelser i immunsystemet
CY1108686T1 (el) (20s)-1 α-υδροξυ-2-μεθυλενιο-19-νορ-δις-ομοπρεγνακαλσιφερολη και οι χρησεις της
DK1082131T3 (da) Immunoregulator
BR0201862A (pt) Composições e métodos para tratar ou prevenir convulsões ou ataques apoplécticos
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
DK1028744T3 (da) Neuronale anvendelser af BMP-11
BR0207693B1 (pt) processo e aparelho para produzir continuamente uma composição elastomérica.
BR0315042A (pt) Terapia para o tratamento de aterosclerose baseada em imunização passiva por peptìdeo
AR029624A1 (es) Anticuerpos o fragmentos de anticuerpos anti-idiotipicos recombinantes y composicion farmaceutica que los contiene
AR030140A1 (es) Composiciones derivadas de la 2-piridinamina y metodos relacionados
BR0315836A (pt) Derivados de [6,7-dihidro-5h-imidazol[1,2-alfa]imadazol-3-sulfonila mino]-propionamida, composição farmacêutica, uso do mesmo, bem como processo para sua preparação
WO2004013303A3 (en) Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease
CO5271719A1 (es) Composicion cosmetica adelgazante que contienen una substancia inductora de la produccion de il-6
BR0108823A (pt) Composição farmacêutica para o tratamento da doença cerebrovascular cognitiva